AP5B1 and Alzheimer disease: To evaluate whether AP5 has the capacity to slow the memory deficits in AD mice models, we chronically administered AP5 to 6-month-old APP/PS1 mice, which were at the early stage of β-amyloidosis for 5 consecutive months.